Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Condition: Healthy Interventions: Drug: Vesicare (Solifenacin Succinate 5 mg)& Betmiga (Mirabegron 50 mg) (Reference first dose); Drug: Mirfenacin MR (Solifenacin Succinate 5 mg& Mirabegron 50 mg) (Test); Drug: Vesicare (Solifenacin Succinate 5 mg)& Betmiga (Mirabegron 50 mg) (Reference second dose) Sponsors: Genuine Research Center, Egypt; Hikma Pharma Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 14, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in Children
Condition: Overactive Bladder Interventions: Drug: Solifenacin Succinate 5 MG Oral Tablet [Vesicare]; Drug: Vitamin D3; Behavioral: Standard urotherapy Sponsor: Xing Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2023 Category: Research Source Type: clinical trials
